Surgery in small cell lung cancer: when and why

Area of Science:

• Oncology
• Thoracic Surgery

Background:

• Small cell lung cancer (SCLC) is typically systemic at diagnosis, historically precluding surgery due to high metastasis rates and poor resectability.
• Radiotherapy and chemotherapy became primary treatments, leading to surgery's decline despite some centers reporting long-term survival in selected SCLC cases.

Purpose of the Study:

• To evaluate the role and rationale for surgical intervention in the management of small cell lung cancer (SCLC).
• To explore surgery's potential in achieving long-term survival, improving local control, and refining diagnosis in SCLC patients.

Main Methods:

• Review of historical series and clinical experience with surgical management of SCLC.
• Analysis of TNM staging system effectiveness for SCLC.
• Consideration of surgical roles in early-stage disease, post-chemotherapy/radiotherapy settings, and mixed histology tumors.

Main Results:

• Historical data suggests long-term survival is achievable with surgery in limited-stage SCLC.
• Surgery can provide accurate pathological response assessment and identify misdiagnosed carcinoids or non-small cell lung cancer (NSCLC) components.
• Local relapse rates of 20%-30% after chemotherapy/radiotherapy suggest a potential benefit for surgical resection, though not definitively proven.

Conclusions:

• Surgery can be considered as a primary treatment for T1 or T2 SCLC with no lymph node involvement, followed by adjuvant chemotherapy.
• For advanced SCLC, surgery may be proposed after chemotherapy for responding patients, preceding radiotherapy, based on pathological stage.
• An intensive multidisciplinary approach, ideally within clinical trials, is recommended for SCLC management involving surgery.